1. Home
  2. CYCN vs GLTO Comparison

CYCN vs GLTO Comparison

Compare CYCN & GLTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CYCN
  • GLTO
  • Stock Information
  • Founded
  • CYCN 2018
  • GLTO 2011
  • Country
  • CYCN United States
  • GLTO Denmark
  • Employees
  • CYCN N/A
  • GLTO N/A
  • Industry
  • CYCN Biotechnology: Pharmaceutical Preparations
  • GLTO Biotechnology: Pharmaceutical Preparations
  • Sector
  • CYCN Health Care
  • GLTO Health Care
  • Exchange
  • CYCN Nasdaq
  • GLTO Nasdaq
  • Market Cap
  • CYCN 8.4M
  • GLTO 6.5M
  • IPO Year
  • CYCN N/A
  • GLTO 2020
  • Fundamental
  • Price
  • CYCN $3.04
  • GLTO $4.72
  • Analyst Decision
  • CYCN
  • GLTO Buy
  • Analyst Count
  • CYCN 0
  • GLTO 1
  • Target Price
  • CYCN N/A
  • GLTO $10.00
  • AVG Volume (30 Days)
  • CYCN 5.8M
  • GLTO 18.1K
  • Earning Date
  • CYCN 03-04-2025
  • GLTO 03-07-2025
  • Dividend Yield
  • CYCN N/A
  • GLTO N/A
  • EPS Growth
  • CYCN N/A
  • GLTO N/A
  • EPS
  • CYCN N/A
  • GLTO N/A
  • Revenue
  • CYCN $194,000.00
  • GLTO N/A
  • Revenue This Year
  • CYCN N/A
  • GLTO N/A
  • Revenue Next Year
  • CYCN N/A
  • GLTO N/A
  • P/E Ratio
  • CYCN N/A
  • GLTO N/A
  • Revenue Growth
  • CYCN N/A
  • GLTO N/A
  • 52 Week Low
  • CYCN $1.27
  • GLTO $4.24
  • 52 Week High
  • CYCN $9.47
  • GLTO $23.50
  • Technical
  • Relative Strength Index (RSI)
  • CYCN 45.87
  • GLTO 44.28
  • Support Level
  • CYCN $2.89
  • GLTO $4.24
  • Resistance Level
  • CYCN $4.80
  • GLTO $5.00
  • Average True Range (ATR)
  • CYCN 0.73
  • GLTO 0.30
  • MACD
  • CYCN -0.10
  • GLTO -0.00
  • Stochastic Oscillator
  • CYCN 18.73
  • GLTO 43.24

About CYCN Cyclerion Therapeutics Inc.

Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop, and commercialize breakthrough treatments for serious and orphan diseases. Its focus is on enabling the full therapeutic potential of next-generation sGC stimulators. Its pipeline products include Olinciguat, Praliciguat, and others.

About GLTO Galecto Inc.

Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of fibrosis and impact a broad range of fibrotic and related diseases, including cancer. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.

Share on Social Networks: